Please login to the form below

Not currently logged in
Email:
Password:

etoricoxib

This page shows the latest etoricoxib news and features for those working in and with pharma, biotech and healthcare.

Grunenthal to market MSD’s pain drug

Grunenthal to market MSD’s pain drug

Acquires rights to Arcoxia in several European countries. Grünenthal has agreed a deal with MSD to market its pain medicine Arcoxia (etoricoxib) in several major European markets. ... In these countries, Grünenthal will hold exclusive promotion and

Latest news

  • EMEA counsels COX-2 action

    With regard to other COX-2 inhibitor pain relievers available within the EU, which include celecoxib (Celebrex; Pfizer), etoricoxib (Arcoxia; Merck &Co), and parecoxib (Dynastat; Pharmacia), the EMEA affirmed that the

  • Merck lambasted over semi-revelation

    The trial, which spread itself across 38 countries, saw Arcoxia (etoricoxib) pitted head to head against diclofenac, an older non-steroidal anti-inflammatory drug (NSAID) already widely prescribed in arthritis communities.

  • RA market to flourish

    Meanwhile, approval of Merck's Arcoxia (etoricoxib) for RA has been delayed in the US pending further safety and efficacy data, although it is already launched in the UK and several

  • News in brief, May 02, 2007

    Regulatory news. FDA rejects Vioxx replacement. The FDA has rejected Merck &Co's request to market Arcoxia (etoricoxib), a replacement for its withdrawn arthritis drug, Vioxx (rofecoxib). ... Wolfe noted that trial data presented by Merck on

  • News in brief, April 11, 2007

    The announcement will not please US pharmaceutical company, Merck &Co, which is waiting for an FDA ruling on its Vioxx (rofecoxib) replacement, Arcoxia (etoricoxib).

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics